What EndoSpan does

EndoSpan Ltd. is an Israeli medical device company headquartered in Herzliya, founded in 2009 and operating with 51–100 employees until its acquisition by Artivion, Inc. in May 2026. The company develops endovascular implantable devices for the minimally invasive treatment of aortic arch disease, with its flagship product, the NEXUS® Aortic Arch Stent Graft System, positioned as the first off-the-shelf endovascular solution approved for chronic aortic arch dissections in patients at high risk for open surgical repair. The system is a modular branched platform combining an Arch Stent Graft with a brachiocephalic trunk branch, an Ascending Curved Stent Graft, and distal extension grafts that align via radiopaque markers and a through-and-through guidewire delivery technique to exclude the diseased arch while preserving antegrade flow to the supra-aortic vessels.

EndoSpan's business model centers on one-time hardware sales of a Class III capital implant to hospitals and surgical centers, supplemented by physician training, KOL proctoring, and clinical-evidence-driven adoption. From 2019 through May 2026, all EMEA commercial activity was executed via Artivion as exclusive distributor, and the company's clinical positioning is anchored by the TRIOMPHE IDE pivotal study in 94 high-surgical-risk patients demonstrating 0% one-year lesion-related mortality and a 1.1% one-year disabling stroke rate. Following FDA Premarket Approval in April 2026, a U.S. commercial launch is planned for January 2027, and the May 2026 acquisition by Artivion for $135 million upfront (plus up to $200 million contingent on U.S. commercial performance) integrates NEXUS alongside Artivion's AMDS and ARCEVO LSA into what Artivion describes as the only globally complete aortic arch portfolio.

Name

EndoSpan

Legal name

Endospan Ltd.

Website

https://endospan.com

Company type

Private

Founded year

2009

Operating status

Acquired

Headcount range

51–100 employees

Short description

EndoSpan is an Israeli medical device company that develops the NEXUS Aortic Arch Stent Graft System, a first-in-class off-the-shelf endovascular implant for minimally invasive repair of chronic aortic arch dissections in high-surgical-risk patients, sold to vascular and cardiovascular surgery programs at tertiary hospitals.

Ownership category

akta.pro rank

Product category

Endovascular Medical Devices (Aortic Stent Grafts)

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts (HLAHAFAF)

akta.pro secondary industry

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)

Keywords

• Endovascular stent grafts
• Aortic arch repair
• Vascular medical devices
• Branched stent systems
• Minimally invasive surgery

Headquarters

HQ city

Herzliya

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others, Supply Chain

Revenue model

1. Medical device (capital implant) sales: Endospan generates revenue primarily through one-time sales of its NEXUS® Aortic Arch Stent Graft System to hospitals and surgical centers. Pre-acquisition, EMEA sales were executed via Artivion as exclusive distributor; post-May 2026 acquisition, revenue flows into Artivion's consolidated medical-device sales line.
2. Distribution / supply agreement revenue: From 2019 through May 2026, Artivion served as Endospan's exclusive distributor of the NEXUS System across EMEA, generating revenue for Endospan through product supply to Artivion at agreed transfer terms.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

EndoSpan develops and manufactures the NEXUS Aortic Arch Stent Graft System, a Class III branched endovascular implant for the minimally invasive treatment of chronic aortic arch dissections in patients at high risk for open surgical repair. The modular system combines an Arch Stent Graft (with a brachiocephalic trunk branch), an Ascending Curved Stent Graft, and distal extension Stent Grafts that connect via radiopaque marker alignment to seal the arch while preserving flow to the supra-aortic vessels.

Differentiator

Problem solved

Functional benefit

Brands

• NEXUS Aortic Arch Stent Graft System: Endovascular branched stent graft system for minimally invasive treatment of aortic arch disease, including chronic dissections, in high-risk patients unsuitable for open surgical repair; received FDA premarket approval in April 2026.

Products and services

• NEXUS Aortic Arch Stent Graft System Class III branched endovascular stent graft system indicated for endovascular treatment of chronic dissections involving the aortic arch in patients at high risk for open surgical repair. Combines an Arch Stent Graft (with a brachiocephalic trunk branch), an Ascending Curved Stent Graft, and distal extension (DE) Stent Grafts connected via radiopaque marker alignment to seal the arch while preserving flow to supra-aortic vessels. Sold to hospitals and tertiary surgical centers for implantation by vascular and cardiovascular surgeons.

Quantifiable outcome

• 0% one-year lesion-related mortality in 94 high-surgical-risk patients (down from 6.4% at 30 days)
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Artivion, Inc.flagshipStrategic or Co-development Partner · 1 January 2019Artivion has been Endospan's exclusive distributor of the NEXUS System across the EMEA region since 2019. Following FDA PMA approval of NEXUS in April 2026, Artivion exercised its option and completed the acquisition of Endospan on May 18, 2026 for a $135 million upfront net purchase price (funded via a previously drawn $150 million delayed draw term loan), with additional contingent consideration of up to $200 million tied to U.S. NEXUS commercial performance over two years. Post-acquisition, Endospan becomes part of Artivion's aortic arch portfolio alongside AMDS and ARCEVO LSA, creating what the company calls the only complete aortic arch portfolio globally.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Others

• Endologix: Kevin Mayberry (Endospan's CEO) was a 14-year Endologix executive. Endologix focuses primarily on infrarenal AAA devices rather than arch, so it is an adjacent vascular medtech company rather than a direct arch competitor, but highly comparable in business model and clinical specialty.

Direct peers

• Cook Medical: Direct competitor with the Zenith thoracic and arch endograft lines, including branched and fenestrated arch systems. Competes with Endospan NEXUS in the endovascular aortic arch repair space serving vascular surgeons at tertiary centers.
• Terumo Aortic: A leading direct competitor in the aortic arch and thoracic stent graft space via its Relay and custom-made arch branch programs (formerly Bolton Medical, Vascutek). Competes with Endospan NEXUS for the same high-risk arch disease patient population and vascular surgeon call points, particularly in Europe.
• W. L. Gore & Associates: Direct competitor via its Gore TAG and Gore Excluder thoracic stent graft systems, with arch branch programs in development. Gore is a long-established incumbent in endovascular aortic repair and competes directly with NEXUS for hospital procurement dollars.
• JOTEC (CryoLife subsidiary): Markets the E-vita and E-nside thoracic stent graft systems used for endovascular aortic arch repair. Competes with Endospan NEXUS in the European market and is pursuing expanded indications for branched arch disease.

Broad incumbents

• Medtronic: Broad incumbent in vascular surgery with the Valiant thoracic stent graft system and Captivia delivery platform. Medtronic is a much larger player with broader endovascular and surgical portfolios, but its thoracic offering overlaps directly with NEXUS in the aortic arch disease indication.
• Artivion: Now Endospan's parent company following the May 2026 acquisition, Artivion also markets the AMDS hybrid prosthesis and ARCEVO LSA — adjacent aortic arch solutions that, combined with NEXUS, form what the company calls the only complete aortic arch portfolio globally.

Emerging players

• Penumbra: A vascular-focused interventional medtech company expanding into adjacent aortic and embolization indications. While not a direct arch competitor today, it represents a relevant emerging player in the broader endovascular interventional space Endospan serves.
• MicroPort Scientific: Has developed the Castor branched thoracic stent graft system, a single-branch arch product that competes with NEXUS in the arch dissection indication. MicroPort is an emerging global player in the thoracic endovascular space.
• Lifetech Scientific: Chinese-headquartered medical device company with aortic stent graft products including the Ankara and Hercules series, with expanding arch indications. Represents a lower-cost emerging alternative to NEXUS, particularly in Asia-Pacific markets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/EndospanLtd
• YouTubeyoutube.com/channel/UCJg9YoqBe3wEm-Qs616tdyw
• Facebookfacebook.com/timeline
• LinkedInlinkedin.com/company/endospan

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EndoSpan